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Summary
Background: Biological therapy is currently widely used to treat IBD. Infliximab,
adalimumab and golimumab are currently licensed anti‐TNF therapies. Biosimilar
anti‐TNF monoclonal antibodies are increasingly used. Anti‐TNF therapies are widely
used and their adverse effects are well characterised, and may cause significant
morbidity and mortality in a small proportion of exposed patients. Gastroenterolo-
gists need to understand the mechanisms for these effects, recognise these swiftly
and manage such events appropriately.
Aim: To cover the range of potential adverse reactions as a result of biologic ther-
apy and specifically management of these events.
Methods: A Medline and Pubmed search was undertaken. Search terms included
were “anti‐TNF,” “infliximab” or “adalimumab” or “golimumab” combined with the
keywords “ulcerative colitis” or “Crohn's disease” or “inflammatory bowel disease”
and then narrowed to articles containing the keywords “complications,” “side
effects” or “adverse events” or “safety profile.” International guidelines were also
reviewed where relevant.
Results: Adverse events discussed in this review include infusion reactions, blood
disorders and infections (including bacterial, viral, fungal and opportunistic infec-
tions) as well as autoimmune, dermatological disorders, cardiac and neurological con-
ditions. Malignancies including solid organ, haematological and those linked to viral
disease are discussed.
Conclusions: Anti‐TNF therapy has wide‐ranging effects on the immune system
resulting in a spectrum of potential adverse events in a small proportion of patients.
Research advances are improving the understanding, recognition and management
of these adverse events.
The Handling Editor for this article was Dr Nicholas Kennedy, and this uncommissioned
review was accepted for publication after full peer‐review.
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1 | INTRODUCTION
The use of biologics is currently approved for moderate‐to‐severe
Crohn's disease (CD) and moderate‐to‐severe ulcerative colitis
(UC).1–9 Infliximab, adalimumab and golimumab are antibodies to
tumour necrosis factor‐α (TNFα). These drugs work on a common
pathway of blocking TNFα, a pro‐inflammatory cytokine closely
linked to acute phase reaction and systemic inflammation, thereby
reducing the degree of damage to tissues. These have been devel-
oped using different techniques therefore conferring different
degrees of immunogenicity. (Infliximab [human‐chimeric], adalimumab
[fully human], golimumab [fully human], certolizumab [recombinant
pegylated humanised Fab’ fragment]).
These medications have transformed medical treatment options
for IBD in recent years and are prescribed in increasing numbers. As
there are less golimumab exposed patients than the other two anti‐
TNF monoclonal antibodies, less adverse effects have been reported
but generally most adverse effects are class effects. Clinicians need
to be aware of and recognise adverse events (AE/AEs) that may result
from the use of these drugs and also have clear management strate-
gies in different scenarios. This comprehensive review summarises a
range of possible AEs providing evidence based guidance where
available and pragmatic guidance for areas where evidence is lacking.
2 | AIMS AND METHODS
A MEDLINE and PubMed search was undertaken by (U.S, C.L) for
articles pertaining to adverse effects of anti‐TNF therapy in IBD.
After an initial title screen, all relevant articles were examined in full.
The main aim of the review is to focus on management of adverse
events caused by anti‐TNF therapy. For clarity, these AEs are dis-
cussed in categories as per systems, alongside recommended course
of action including any further investigations or management. Where
relevant, this manuscript also refers to international guidelines.
2.1 | Noninfectious complications and management
strategies
2.1.1 | Hypersensitivity reactions
Hypersensitivity reactions vary widely in presentation, ranging from
acute infusion reactions to delayed hypersensitivity.
1. Type I acute hypersensitivity reactions (IgE mediated) present as
anaphylaxis
2. Type II are cytotoxic; complement‐mediated
3. Type III are immune‐complex related presenting as serum sickness
4. Type IV are cell‐mediated delayed hypersensitivity; mediated by
T lymphocytes
Acute infusion reactions (IR) are defined as those which occur
during or within 24 hours of the infusion. The symptoms vary and
reactions can range from mild (flushing, dizziness, headache, itching,
rash) to severe (anaphylactic‐like).2 Acute infusion reactions are rela-
tively common, estimated to occur in up to 5% of infusions, with
less than 1% of all infusions resulting in a severe reaction.3
Patients with antibodies to infliximab are at an increased risk of
infusion reactions4 and case reports suggest hypersensitivity to adali-
mumab are also associated with adalimumab antibodies.5 A review by
the Food and Drug Administration (FDA) reported that injection site
reactions were more common with adalimumab6 with higher reporting
odds ratio(ROR) in the 20‐29 years age group (ROR = 16.18). The
ROR was seen to reduce with increasing age.6 Injection site reactions
to golimumab in the PURSUIT study were low at 3.4% with no
reported anaphylaxis or delayed hypersensitivity to 6 weeks.7 Delayed
reactions (24 hours to 14 days) presenting with arthralgia, myalgia,
fever, fatigue and rash are much rarer (<1%).3 The pathophysiology of
immunological features are not completely understood.8
Management
The management of infusion reaction (IRs) is generally similar regard-
less of which agent has caused it. Typically, symptoms improve sub-
stantially or resolve completely after infusion rate adjustments and
treatment with paracetamol, antihistamines or corticosteroids are
provided. Evidence to support the use of premedication with corti-
costeroids or antihistamines is limited, with patients still experiencing
infusion reactions despite premedication9 and therefore should be
considered on an individual basis. Injection site pain due to adali-
mumab can be reduced by using low volume formulations which are
free from citrate buffers, with no change in efficacy.10
In severe acute reactions, it is recommended that infusion is
stopped and focus should be on maintaining airway, circulation as
per standard anaphylaxis guidelines.11 (Table 1) Delayed infusion
reactions are typically managed by antihistamines, paracetamol and
corticosteroids. A systematic review looked at management of infu-
sion reactions and presented useful algorithms to manage mild, mod-
erate and severe reactions.12 These algorithms are simple, and a
pragmatic tool to use for the vast majority of reactions seen in clini-
cal practice.12 After a hypersensitivity reaction, it is pragmatic to
obtain therapeutic drug levels and anti‐drug antibody levels.
2.1.2 | Haematological effects
Leucopenia
Neutropenia has been reported in anti‐TNFα treatment‐exposed
patients, with up to 20% of patients developing neutropenia on at
least one occasion.13 TNFα up‐regulates other proinflammatory
cytokines, including interleukin‐1 (IL‐1), IL‐6, IL‐8, and granulocyte–
macrophage colony‐stimulating factor, involved in the differentiation
and maturation of haematopoietic progenitor cells.14 TNFα blockade
could mediate bone marrow failure by inhibiting stem cell differenti-
ation.15 However, the reduction in neutrophil count following TNFα
inhibitor therapy is not seen for other cells from the same lineage
(myeloid progenitor cell), specifically basophils, eosinophils and
monocytes. The risk of neutropenia is significantly higher in patients
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with a low baseline neutrophil count or a previous history of neu-
tropenia.13,16
Thrombocytopenia
Isolated thrombocytopenia following the use of anti‐TNF drugs17,18
has been reported. There are multiple hypotheses as to the possible
aetiology, including autoimmune platelet destruction secondary to
antiplatelet antibodies, immune complexes triggering the comple-
ment cascade, another unknown autoimmune mechanism, or idiosyn-
cratic reaction.18
Anaemia
Anaemia is considered a marker of active disease in IBD and there-
fore clinicians need to first consider this as an aetiology. The inci-
dence and prevalence of anaemia was approximately 19% and 28%,
respectively, in a recent population based cohort study. Crohn's with
stricturing disease and long‐standing UC were recognised as risk fac-
tors.19 One study showed only marginal improvement in anaemia
after treatment with anti‐TNF therapy suggesting that disease activ-
ity in itself has a major role to play.20
In this section, anaemia directly attributable to biologics is dis-
cussed, which is rare. There are sporadic case reports of aplastic
anaemia with infliximab, more commonly in patients with rheumatoid
arthritis than IBD.21 A single case of infliximab induced autoimmune
haemolytic anaemia (in a patient found to be anti‐nuclear antibody
(ANA) positive 1:40) has also been reported.22
Management of haematological effects
All patients starting anti‐TNF therapy should have a baseline com-
plete blood count with repeat testing every three to six months. At
the onset of neutropenia, the anti‐TNF should be withheld if the
neutrophil count is deemed too low by the clinician. The patient
should be left drug‐free until neutrophil counts recover and anti‐TNF
therapy restarted when deemed clinically safe. Neutropenia can
occur in patients managed with combination therapy with an anti‐
metabolite and this should be borne in mind and should be
discontinued first. A neutrophil count less than 1000 per mm3
should raise concern and <500 per mm3 should lead to discontinua-
tion of incriminating drugs and close monitoring. Rare anti‐TNF
induced systemic lupus erythematosus should be excluded and sar-
gramostim is rarely necessary after drug discontinuation.
Thrombocytopenia can be managed by drug cessation, corticos-
teroid therapy or rescue therapy with intravenous immunoglobulin
(IVIG). Thrombocytopenia has been reported to be prolonged after
cessation of therapy. In severe cases this could persist for up to
6 months and also preclude exposure to any further anti‐TNF
agents.18 This is likely to be a class effect and rechallenge with same
class could be risky and therefore discouraged.17 In severe cases,
specialist haematology input is suggested.
Anaemia in IBD is more commonly seen due to ongoing disease
activity. Clinicians should first consider assessment for disease and
strategies to control and manage anaemia secondary to disease as
per guidelines. As anaemia related only to therapy is rare, there is no
specific guidance in current literature regarding future therapy with
anti‐TNF. Cessation of therapy would depend on careful physician‐
patient discussion taking into account the severity of anaemia and
alternative treatment strategies. Involving haematologist in refractory
cases would be prudent. (Table 2).
2.1.3 | Dermatological effects
In addition to skin malignancies anti‐TNF therapy can cause a wide
range of dermatological conditions. Most notably they include local
skin irritation or reaction, increased skin infection rates, psoriasis,
eczema, acne and alopecia. Other rare dermatological complications
include erythema nodosum,23 granuloma annulare and interstitial
granulomatous dermatitis. Although some of the above complications
are also seen as extraintestinal manifestations of disease, temporal
association with biologic therapy should help differentiate disease
related complications from drug related complications.
Psoriasis and psoriasiform reactions can occur directly as a result
of anti‐TNF therapy, which interestingly is used by dermatologists to
TABLE 1 Hypersensitivity reactions to anti‐TNF therapy
Complication Diagnosis Management strategy
Type 1 Hypersensitivity
This is more common when antibody titres are
high. Incidence is higher during reintroduction of
drugs
 Clinical diagnosis Serum mast cell tryptase Detection of antibodies on serum
analysis where available
1. Mild reactions: Slow infusion rates
2. Consider hydrocortisone injections as a
preadministration medication
3. Anaphylaxis reactions: Treat as per ALS
pathway with adrenaline, steroids and anti‐
histamines
Type 2 Complement mediated
Nonspecific symptoms
 Detection of antibodies on serum
analysis where available
1. Symptomatic treatment
2. Consider stopping treatment
Type 3 Immune‐complex mediated
Serum sickness
 Difficult to detect on assays, immune
complexes known to adhere to
membranes
1. Symptomatic treatment
2. Consider stopping the drug and switch if
antibodies are confirmed
Type 4 T‐cell mediated
Delayed hypersensitivity reaction (after 24 h up
to 14 d postinfusion)
 Clinical diagnosis 1. Symptomatic management
2. Consider stopping drug
anti‐TNF, anti‐tumour necrosis factor; ALS, advanced life support.
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treat severe cases of psoriasis. Psoriasis is a relatively common side
effect of anti‐TNF therapy, with 1.5%‐5% of patients developing this
manifestation.24 It is seen most commonly in females, typically 2‐
6 months following initiation of therapy.25 A nation‐wide cohort
study reported incidence rates of anti‐TNF induced psoriasis in IBD
at 0.5% per patient‐year.26 A more recent study shows a much
higher incidence at 10.5%,27 but psoriasiform lesions are more com-
mon than psoriasis and have distinctive features. According to cur-
rent evidence, females, smokers, and patients with fistulising disease
appear to be at risk.27 In addition to anti‐TNF induced psoriasis, pso-
riasiform and drug‐induced psoriasiform lesions have been well‐
recognised. Psoriasiform drug reactions can be distinguished histo-
logically from psoriasis and resolve swiftly on cessation of drug ther-
apy. Rechallenge results in recurrence of the lesions. The
psoriasiform lesions could be secondary to infections and resolve on
its treatment, though the infective origin of these are not always
clear nor are their implications.25
The exact mechanism triggering de novo psoriasis remains
unclear, although it has been postulated to be secondary to
increased cutaneous expression of interferon alpha (IFNα). IFNα is
released from dendritic cells to recruit T cells and proinflammatory
cytokines IL‐12 and IL‐23. TNFα would normally block IFNα expres-
sion and so anti‐TNFα results in up‐regulation of IFNα.24 Higher
levels of IFNα are seen in anti‐TNF induced psoriasis than idiopathic
psoriasis.25
Management
Management of psoriasis due to anti‐TNF depends on severity of
symptoms. Milder cases of psoriasis can be treated clinically with
topical therapy without cessation of anti‐TNF, however, more sev-
ere cases may require anti‐TNF withdrawal.24 About 80% of
patients respond to a combined approach of steroids and biologics
withdrawal.26 The use of another anti‐TNF agent may result in
recurrence of psoriasis in majority of cases (52%).25 Ustekinumab
has been used in the treatment of CD28 and psoriasis.29 There
have been rare reports of paradoxical worsening of psoriasis with
ustekinumab but not known to cause drug‐induced psoriasis.21
Ustekinumab is potentially an attractive option for treatment of
TABLE 2 Haematological complications with anti‐TNF therapy
Complication Diagnosis Management strategy
Leucopenia
Neutropenia
 Blood count monitoring 1. If <safety threshold: stop drug, monitor blood count
2. Restart drug when counts are within normal range
3. Monitor
4. Consider G‐CSF
Thrombocytopenia  Blood count monitoring Establish temporal relationship to drug Secondary cases of low platelets to be
excluded including concomitant drug
therapy
1. If <safety threshold: stop drug, monitor platelet count
2. Consider IV immunoglobulins and steroids
3. Consider switching to different class of biologic
Anaemia
Drug related anaemia is
rare but aplastic anaemia can be
serious
 Blood count monitoring Bone marrow aspiration in refractory
cases
1. If aplastic anaemia: withdraw and stop drug
2. Refractory cases warrant specialist haematology
assessment
G‐CSF, Granulocyte‐colony stimulating factor.
TABLE 3 Dermatological adverse effects with anti‐TNF therapy
Complication Diagnosis Management strategy
Psoriasis
Relatively common (1.5%‐5% of
patients on anti‐TNFs)
 Clinical diagnosis Histology of skin lesions Establish temporal relationship between
initiation of biologic therapy and development
of psoriasis
1. Specialist involvement from dermatology
2. In mild cases: topical steroid therapy
3. In severe cases: stop drug and consider alternatives
such as Methotrexate
4. Ustekinumab for managing both conditions is a
viable alternative
Psoriasiform lesions
Common
 Clinical diagnosis Consider skin infections causing the rash
1. Consider stopping drug in severe cases.
2. Responds well to cessation of drug therapy
3. Treat skin infection as appropriate
Erythema Nodosum
Granuloma Annulare
Interstitial Granulomatous
Dermatitis
Very rare
 Clinical diagnosis 1. No clear evidence on management as these
conditions are rare
2. Specialist dermatology involvement is advised
3. Usually not necessary to withhold or stop drug
4. Clinician decision based on risk: benefit assessment
anti‐TNF, anti‐tumour necrosis factor.
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refractory anti‐TNF induced psoriasis25 requiring withdrawal of pri-
mary drug. Methotrexate has been used but does not appear to
be effective in all cases.26 It is a useful option to have in selected
cases (Table 3).
2.1.4 | Autoimmune‐like disorders
Autoimmune‐like disorders/syndromes are a group of conditions
observed in patients on anti‐TNF therapy. This was first described in
initial studies of infliximab in patients with rheumatoid arthritis.30
These disorders include a variety of conditions such as positive anti-
bodies eg, anti‐nuclear antibodies, anti‐double stranded DNA anti-
bodies (dsDNA) (commonly IgM type), on immunological testing,
various systemic or organ‐specific autoimmune diseases as docu-
mented in the BIOGEAS registry, drug‐induced systemic lupus ery-
thematosus (DIL) called lupus‐like syndrome, vasculitis,
antiphospholipid syndrome, sarcoidosis, interstitial lung disease, opti-
cal neuritis, inflammatory ocular disease, multiple sclerosis (MS)‐like
central nervous system demyelination, and peripheral neu-
ropathies.31
William et al described anti‐TNF induced lupus (ATIL) based on
the severity of symptoms displayed and suggested that ATIL is a dis-
tinct syndrome in itself32 and are likely to be different from drug
induced lupus. In a pooled analysis across various diseases, studies
which included patients with IBD showed that whilst ANA positivity
was very common after anti‐TNF therapy (40%‐56%), asymptomatic
anti‐nuclear antibodies or anti‐double stranded DNA antibodies
require observation but not discontinuation of anti‐TNF. The full
range of symptoms of ATIL was seen in only about <1% of
patients.32 Most patients with full blown ATIL had fever, rash, arthri-
tis and haematological abnormalities.
A large case series was reported by Costa et al comparing drug‐
induced lupus secondary to anti‐TNF and classic drug‐induced
lupus.33 Both groups had similar systemic features and symptoms
but there were some features that distinguished one group from the
other. 72% of patients with anti‐TNF drug‐induced lupus had cuta-
neous manifestations compared to about 25% in classic drug‐induced
lupus group. Classic drug‐induced lupus was not usually associated
with antibodies to dsDNA and extractable nuclear antigen (ENA) or
with complement consumption. 90% of anti‐TNF drug‐induced lupus
patients were positive for anti‐dsDNA antibodies and >50% had
anti‐extractable nuclear antigen antibodies and decreased serum
complement levels.33
Management
The management of autoimmune‐like disorders/syndromes secondary
to anti‐TNF therapy requires a customised therapeutic approach
according to severity of the induced autoimmune disease. ATIL
should be considered a distinct condition and managed accordingly.
There are features which could help distinguish this. The incidence/
prevalence of dsDNA antibodies and hypocomplementaemia is
greater in ATIL, whilst anti‐histone antibodies, the hallmark of classic
drug‐induced lupus, are less commonly found.32
In patients with a positive ANA, it is not in itself an indication
for discontinuation of therapy. In the presence of mild features, ces-
sation of anti‐TNF therapy is probably sufficient. However, it can be
continued in patients with isolated cutaneous lesions or immunologi-
cal alterations in whom biologics are thought to be essential to treat
underlying disease, with closer follow‐up. In patients with involve-
ment of internal organs (kidney, lungs, nervous system), cessation of
therapy is mandatory with addition of corticosteroids and/or
immunosuppressive agents.30,33 After discontinuation of the incrimi-
nating anti‐TNF the prognosis is generally very favourable. The pres-
ence of diagnosed SLE is a contraindication to anti‐TNF exposure.
2.1.5 | Cardiac effects
It was reported that worsening cardiac failure was a possible adverse
event in a randomised controlled trial investigating the use of anti‐
TNF therapy in cardiac failure.34 Majority of patients enrolled were
New York Heart Association III (NYHA) at baseline and the group
receiving high dose infliximab (10 mg/kg) were adversely affected
with an increased likelihood of hospitalisation, high frequency of
worsening heart failure, with the risk of adverse clinical events per-
sisting for up to five months after cessation of therapy.34 The exact
mechanism of heart failure with anti‐TNF use remains unclear.
There have been case reports of second degree and complete
heart block after infliximab therapy but these are rare.35 This is more
likely to happen in rheumatological conditions as there may be
underlying cardiac involvement. A single blind prospective study
which included rheumatological conditions concluded that new‐on-
set cardiac arrhythmias, particularly ventricular tachyarrhythmia,
developed during infliximab infusion, but their incidence did not
achieve statistical significance.36 Acute coronary syndrome following
infusion has been reported but this too is very rare.37 The rarer car-
diac effects are based on reports with a very small number of
patients, mostly from the rheumatology cohort who are at higher
risk of having cardiac disorders.
Management
Current guidance recommends that use of anti‐TNF therapy is best
avoided in those with NYHA III/IV heart failure.38 All patients who
develop heart failure while on an anti‐TNF agent should discontinue
therapy, conventional medication for treatment of heart failure
started and specialty advice sought. An alternate class of agent
should be considered for the primary disease process. It is still
unclear whether infliximab can be used safely in patients with
asymptomatic left ventricular dysfunction or mild symptoms of heart
failure (NYHA class I/II).38 For patients commencing anti‐TNF therapy
who have specific cardiac risk factors such as hypertension, valve
disorders or ischaemic heart disease, our recommendation is that
clinicians should get a baseline electrocardiogram to record QT inter-
val among other features and clinically assess the patient for any
features of pre‐existing heart failure that may preclude therapy. Not
all studies have substantiated an association of anti‐TNF therapy
with heart failure and this is rare in patients with IBD (Table 4).
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2.1.6 | Neurological effects
Demyelination
Demyelination has been recognised as a complication of anti‐TNF
therapy. A review of FDA adverse event recording system showed
that among 772 reports of neurological complications, 18% of
patients had IBD. About 36% of patients had received infliximab and
peripheral neuropathy was the most commonly reported event.39
Demyelination can occur in central or peripheral nervous systems.40
It remains unclear as to whether the relationship is truly causal, or
whether anti‐TNF triggers an existing tendency for demyelination.
Management
Patients who have a family history of demyelination disorders may
be at higher risk and this should be considered before the therapeu-
tic agent is chosen.41 It is standard guidance to avoid anti‐TNF ther-
apy in patients with concomitant multiple sclerosis or history of
optic neuritis. In patients who develop neurological deterioration and
suspected demyelination during therapy, treatment with biologic
agent should be discontinued41 and specialist neurology opinion
should be sought. The clear relationship between demyelinating
events and anti‐TNF can be difficult to establish as IBD may also be
associated with demyelination. Treatment with corticosteroids, IVIG,
and plasmapheresis are rarely necessary (Table 5).
2.2 | Infections and management strategies
Biologics are strong immunosuppressive agents and can increase risk
of infection depending on their mechanism of action. Tumour necro-
sis factor‐α (TNFα) is essential for activation, differentiation, and
recruitment of several immunological cell types; it has a role in gran-
uloma formation, maintenance of granuloma integrity,42 and host
response to mycobacteria and intracellular organisms.43 A recent
meta‐analysis found that anti‐TNF therapy was associated with a
greater infection risk than placebo in treating UC but anti‐integrin
therapy was not; neither class showed an increased infection risk
over placebo in CD.44 Other studies have confirmed increased risk in
both forms of IBD.
A recent systematic review by Wheat et al concluded that at
present there is no evidence of a higher odds of serious infection
from the newly available biologic therapies such as vedolizumab and
ustekinumab compared to anti‐TNFs.45 Feagan et al report that
infections in patients exposed to ustekinumab for CD is no higher
than placebo in UNITI trials46 and Wils et al reported only one seri-
ous pulmonary infection in a cohort of 122 ustekinumab exposed
patients, followed up over 2 years.47 Bye et al reported an increased
risk of Clostridium difficile infection with vedolizumab therapy but
concomitant steroid and narcotic analgesics were identified as risk
factors.48
2.3 | Bacterial infections
Patients receiving anti‐TNF therapy have been reported to acquire
both common and uncommon bacterial infections. Common sites for
infection include upper and lower respiratory tracts, skin and subcu-
taneous tissue, urinary tract and GI tract.49
2.3.1 | Management
Common infections are treated with oral antibiotics as per local
guidelines. A pragmatic approach would be to have a lower
TABLE 4 Cardiac adverse effects with anti‐TNF therapy
Complication Diagnosis Management strategy
Cardiac failure  Clinical diagnosis Objective assessments with
investigations
1. Avoid anti‐TNFs in NYHA III and IV heart
failure
2. If drug precipitates heart failure: stop the drug
3. Treat for heart failure with diuretics and early
specialist involvement
4. Switch to another class of drugs
Second and third‐degree heart block
More commonly seen in the treatment of rheumatological
conditions; less so with IBD
 12 Lead ECG Cardiac monitoring
1. Monitor patients for features of
decompensation
2. Specialist involvement for further management
3. Stop drug and switch to another class
Arrhythmias
More commonly seen in the treatment of rheumatological
conditions; less so with IBD
 12 Lead ECG Cardiac monitoring
1. Usually transient and does not need any
specific management
2. If transient episodes are self‐limiting: consider
continuing drug
3. If persistent: seek specialist cardiology opinion
anti‐TNF, anti‐tumour necrosis factor; NYHA, New York Heart Association.
TABLE 5 Neurological reactions with anti‐TNF therapy
Complication Diagnosis Management strategy
Demyelination
Known to
worsen
demyelination
in patients
with multiple
sclerosis
 Clinical
diagnosis Nerve
conduction
studies MRI
1. Stop drug and consider
alternatives
2. Seek specialist Neurology
involvement
3. Consider pulse therapy with
high dose methylprednisolone
4. Consider IV Immunoglobulin
MRI, magnetic resonance imaging.
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threshold to start treatment and switch to intravenous drugs in the
presence of systemic symptoms. In severe sepsis requiring prolonged
antimicrobial treatment, anti‐TNF therapy may have to be withheld.
Restarting therapy can be considered once patients are afebrile,
white cell counts within normal range and relevant imaging (CT, MRI
pelvis) show no evidence of infective source. (Table 6).
2.3.2 | Uncommon infections
Several nonmycobacterial intracellular infections, including listeriosis
caused by Listeria monocytogenes and legionnaires’ disease most
often caused by Legionella pneumophilia, have been associated with
anti‐TNF therapy.50 Listeria sepsis and meningitis have been
described in patients receiving anti‐TNF drugs51 and in 2011, the
FDA added a boxed warning about the risk of listeriosis and legion-
naires’ disease for the entire class of TNFα inhibitors.52 There are a
few case reports of listeriosis complicating anti‐TNF therapy. Liste-
riosis carries significant mortality, therefore requiring prompt diagno-
sis and aggressive treatment. The risk appears to be higher during
the first year of therapy.53 Anti‐TNF should be discontinued till the
patient recovers from listeriosis.
2.3.3 | Management
Suspicion of infection requires confirmatory testing and treatment
using standard antibiotic regimes depending on pathogen isolated.
Listeriosis is more likely to be seen in patients consuming mould‐
ripened cheese regardless of whether it is from pasteurised or
unpasteurised milk and also from cold smoked gravad fish.54 In one
study from United States, unpasteurised milk and dairy products
were noted to significantly increase the risk of infections caused by
Escherichia coli, Salmonella, and Campylobacter.55 In view of this over-
all increased risk of infections, it is safer for patients to avoid con-
sumption of unpasteurised milk whilst on anti‐TNF drugs.
2.4 | Mycobacteria and tuberculosis
Tuberculosis (TB) caused by mycobacterium bacilli is a serious infec-
tion which carries significant morbidity. TNFα is necessary for a Th1‐
based cell‐mediated immune response important in activating macro-
phages to kill intracellular mycobacteria, and limit spread by forma-
tion of granulomas.56,57 The majority of exposed immunocompetent
hosts have latent TB (LTB) which can subsequently lead to reactiva-
tion of infection if there is compromise to the immune system, such
as initiation of anti‐TNF drugs.58 It is therefore critical to identify
and treat LTB prior to starting anti‐TNF therapy.58
An association between anti‐TNF therapy and development of
TB was noted when the FDA MedWatch spontaneous reporting sys-
tem demonstrated 70 TB cases in a median of 12 weeks after initial
infliximab exposure, in 2001.59–68 Both extrapulmonary and dissemi-
nated TB are more common in patients treated with anti‐TNF ther-
apy, compared with immunocompetent patients.59,60 It has been
hypothesised that the early occurrence of TB after infliximab may
suggest reactivation of LTB rather than a de novo infection.60 Due
to the high risk of reactivation, screening for TB is recommended
prior to starting anti‐TNF.
The diagnosis of LTB can be difficult and should include a combi-
nation of detailed history and supportive investigations. At present,
IGRA (interferon gamma release assay) and TST (tuberculin skin test)
are commonly used in most centres. In a study by Mariette et al
which looked at how effective the available tests are, it was noted
that when one of the IGRA tests replaced TST, it influenced the
TABLE 6 Bacterial infections with anti‐TNF therapy
Complication Diagnosis Management strategy
Common bacterial infections
Respiratory tract  Clinical diagnosis Relevant investigations depending on symptoms
1. Appropriate antibiotics based on site of infection
2. Consider early therapy
3. If any signs of sepsis: stop drug
4. Restart biologics when good evidence of
resolved infection. (WCC, imaging)
Urinary tract
Gastrointestinal
Cellulitis
Serious bacterial infections
Listeriosis  Serology CT/MRI of brain Lumbar puncture if meningitis suspected
1. Appropriate antibiotics based on sensitivity
2. Seek specialist microbiology adviceLegionnaires’
disease
Septic Arthritis
Septicemia
Tuberculosis (TB)
Latent TB Re‐
activation
 Risk assessment based on initial screening with Quantiferon or
T‐Spot testing Thorough history and risk factor assessment Chest X‐ray
1. If positive or indeterminate: involve specialists
2. Treat as per ECCO guidelines and British
Thoracic Society Guidelines
3. Risk: Benefit analysis by clinician
4. Consider alternative therapy ie, vedolizumab or
ustekinumab
WCC, white cell count.
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decision made by physicians, leading to 28% fewer patients receiving
anti‐TB (ATB) prophylaxis.61 This is likely because IGRA tests are
more specific. As per this study, IGRA does not appear to be
affected by corticosteroid or immunosuppressant therapy.61 How-
ever, this may not always be the case as shown in an ex vivo study
in which corticosteroids and infliximab reduced the performance of
IGRA.62 At present, IGRA is possibly more reliable than the other
options available. TST is less specific and can be less frequently posi-
tive due to corticosteroid or immunosuppressant therapy and this
should be borne in mind. Based on their findings, Mariette et al pro-
posed an algorithm for assessing patients, which is now generally
applied prior to starting anti‐TNF therapy.61 All patients should
undergo appropriate history ± chest X‐ray. For those with a positive
history or X‐ray, treat with ATB prophylaxis. For those with negative
history, check with IGRA test (authors recommend GOLD, followed
by T‐SPOT if indeterminate). Those with negative results require no
further screening. Those with positive results require ATB prophy-
laxis. Patients with indeterminate GOLD and T‐SPOT test should
undergo TST testing. Negative results require no further action, but
a positive TST should be treated with prophylaxis.61
In patients who have a positive TST and negative IGRA, the
degree of clinical suspicion should guide management, based on his-
tory and chest X‐ray with a very low threshold to treat the patient.
Generally, performing both TST and IGRA is not recommended. An
initial indeterminate borderline IGRA can be followed up with TST
and if the latter is positive the patient should be treated. The CDC
recommend testing with either IGRA or TST, but a combination of
both may be appropriate where clinical suspicion of LTB is high, or
risk of subsequent LTB reactivation may result in a poorer outcome
(such as those on immunosuppressants).63
2.4.1 | Management
Guidelines by European Crohn's and Colitis organisation (ECCO)26
and British Thoracic Society (BTS)58 on screening and management
of TB are similar in principle, suggesting treatment of LTB prior to
initiation of anti‐TNF therapy with a complete therapeutic regimen.
If there is clinical suspicion ± radiographic changes suggestive of TB,
patients should be referred for treatment of LTB.58 Other patients
should undergo LTB screening tests. The optimal screening strategy
for these patients is still debatable.
After diagnosis of latent TB in a patient with IBD, appropriate
treatment should be administered for at least 3 weeks prior to com-
mencement of anti‐TNF therapy64,65; however, if treatment with
anti‐TNF therapy is considered very urgent simultaneous treatment
for latent TB and IBD may be considered. Alternative therapies such
as vedolizumab or ustekinumab may also be considered for UC or
CD. Short latent TB therapies are increasingly considered such as
rifampicin for 4 months or isoniazid plus rifampicin for 3 months as
adherence to 9 months of daily isoniazid poses challenges.66,67 Expo-
sure to active TB during anti‐TNF therapy should lead to prompt re‐
evaluation for latent or active TB. In case of active TB, anti‐TNF
should be discontinued and active TB treated. If absolutely
necessary, anti‐TNF may be resumed after at least 2 months of anti‐
TB therapy with satisfactory response, though it may sometimes be
resumed earlier if absolutely necessary. Increasingly other mono-
clonal antibodies such as ustekinumab or vedolizumab are being con-
sidered. Annual retesting for LTB in patients on anti‐TNF therapy
depends on risk factors for exposure to TB and desirable in geo-
graphical areas with endemic TB. (Table 6)
2.5 | Viral infections
A majority of human viral infections are self‐limiting but some are
capable of causing chronic infection (eg human immunodeficiency
virus [HIV], hepatitis B virus [HBV], and hepatitis C virus [HCV]).
There are viruses linked to malignancy, such as Epstein‐Barr virus
(EBV) and human papilloma virus (HPV). EBV will be discussed in
more detail in “malignancy” section of this text.
2.5.1 | Varicella zoster virus (VZV) and Shingles
This can present with severe or disseminated disease if contracted
while on anti‐TNF therapy.68 In one study, the prevalence of prior
varicella zoster virus (VZV) infection among IBD patients was greater
than 90%69 and it was not noted that a significant number had a
VZV IgG negative status. It is known that patients with IBD are at a
higher risk of VZV infection and more so when on immunosuppres-
sive therapy.70,71
Herpes zoster or shingles is caused by reactivation of VZV. The
incidence of shingles is again increased in patients with IBD, the
elderly population at particular risk. In a study looking at herpes zos-
ter in IBD, it was seen that patients with CD were at higher risk;
age >45 years, treatment with corticosteroids for >2 weeks, thiop-
urine therapy were associated with increased risk of infection.72
Long et al reported similar findings and also noted that patients on
anti‐TNF therapy for IBD are at higher risk of herpes zoster with an
odds ratio of 1.81 (95% CI: 1.48‐2.21).73
2.5.2 | Management
Immunocompromised patients exposed to VZV should be treated
with VZV immunoglobulin.74 Patients who contract VZV or shingles
during a period of immunosuppression require antiviral therapy. If
oral therapy is appropriate, valganciclovir should be considered as
this provides higher oral bioavailability than aciclovir.65 (Table 7)
Prevention of infection is possible due to availability of effective
vaccines. It is recommended that all patients are screened for evi-
dence of past infection prior to starting biologics or immunosuppres-
sives including steroids. ECCO suggest that in seronegative patients
two‐dose course of varicella vaccine should be given at least
3 weeks prior to commencement of therapy.65 If subsequent immu-
nisation is necessary, it can be administered after a 3‐6 month cessa-
tion of all immunosuppressives as both the VZV and shingles
vaccines are live vaccines,65 although there is emerging evidence
that administration of live zoster vaccine to patients already on anti‐
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TNF therapy did not result in disease and there was expected
immune response to the vaccine.73
2.5.3 | Hepatitis B
Tumour necrosis factor‐α (TNFα) and interferon (IFN)γ are released
by cytotoxic T lymphocytes on antigen recognition of the hepatitis
B virus, activating two viricidal pathways, plus antigen nonspecific
T cells & macrophages.75 Reactivation of HBV may occur during
anti‐TNF therapy, or on subsequent withdrawal (secondary to
immune reconstitution). Reactivation of chronic HBV carriers (hep-
atitis B surface antigen (HBsAg) positive, undetectable HBV DNA,
normal LFTs) after anti‐TNF therapy has been reported.76 Patients
who have had HBsAg seroconversion following exposure to HBV
[HBsAg negative, anti‐HBc (core antibody) positive and anti‐HBsAg
antibody positive] have been successfully treated with anti‐TNF
therapy without HBV reactivation during follow up.77 Chronic
active HBV patients already successfully controlled with antiviral
therapy prior to introduction of anti‐TNF show no deterioration in
the viral load or liver enzymes.78,79 A comprehensive review by
Pattullo80 looked at incidence & prevalence of HBV reactivation
in IBD when treated with immunosuppressants without HBV pro-
phylaxis; risk stratification of patients was also done based on
type of biologic therapy.80 The incidence of immunosuppression
related HBV reactivation was noted to be about 36% in HBsAg
positive patients. The overall prevalence of HBV in IBD ranged
from 0.6%‐17% for HBsAg positive patients, and 1.6%‐42% for
HBsAg negative/anti‐HBc positive patients. The risk estimate of
HBV reactivation was reported to be moderate (1%‐10%) with
anti‐TNF.80
2.5.4 | Management
All patients should be screened prior to initiation of therapy,
although which patients should receive antiviral therapy remains
unclear. Screening should be carried out checking for hepatitis B sur-
face antigen, antibody to surface antigen, and anti HB core antibody
levels and if HBsAg or anti‐HBc is positive, DNA quantification
should be done.65 Chronic HBV carriers and those with HbsAg sero-
conversion should be considered for antiviral therapy and hepatology
involvement. It is recommended that patients who are due to start
biologics (moderate risk of reactivation) are given anti‐viral prophy-
laxis if they are HBsAg positive and continued for at least 6 months
after completion of immunosuppressive therapy.80 In case of reacti-
vation, it is recommended that one of the antivirals is started and
continued for at least 6‐12 months after immunosuppressive therapy
has been stopped. The antiviral medication of choice may depend on
the patient's individual circumstances and the planned duration of
immunosupression.81 Entecavir and tenofovir are now preferred anti‐
virals in IBD patients due to their rapid onset of action, highest anti‐
viral potency with low incidence of resistance.65 Whilst lamivudine is
used, this has its limitations if long term therapy is required, as resis-
tance can occur in up to 30% of patients after 1 year and 70% after
5 years.81 Peginterferon‐alpha‐2a (IFNα) is best avoided due to the
risk of myelosuppression and also risk of exacerbating CD.65
2.5.5 | Hepatitis C
Tumour necrosis factor‐α (TNFα) appears to be involved in the
pathogenesis of HCV, with patients with higher serum TNFα levels
less likely to respond to anti‐viral therapy.82 TNFα blockade may
TABLE 7 Viral infections in the use of anti‐TNF therapy
Complication Diagnosis Management strategy
Varicella
Relatively common
 Clinical diagnosis Serology testing available
1. Treat with varicella immunoglobulin
2. Antimicrobial therapy with valganciclovir
Chronic stable HBV
Reactivation of chronic
infection
 Screening for HBV mandatory Close monitoring of liver function and viral load
1. Joint care with Hepatologist
2. May require treatment with antivirals
3. Biologics can be continued unless acute fulminant liver
failure suspected
Chronic active HBV on
antiviral therapy
 Screening for HBV mandatory Close monitoring of liver function and viral load
1. Continue antivirals
2. Entecavir and tenofovir drugs of choice
Hepatitis C  Screening for HCV recommended prior to anti‐
TNF therapy Close monitoring of LFTs and HCV RNA Load in
HCV infected patients
1. Joint care with Hepatologist
2. Continue biologic with close monitoring
3. No contraindication for therapy
Cytomegalovirus (CMV)  Check serology for CMV IgM and viral PCR Supported by tissue diagnosis with histology and
immunohistochemistry
1. Treatment with IV ganciclovir and switch to oral
valganciclovir for total of 2‐3 wk
2. Use foscarnet as per sensitivities
3. If systemic CMV infection: consider stopping anti‐TNF
Human immunodeficiency
virus
 Close monitoring in addition to CD4+ counts 1. Continue biologics when HAART established and CD4+
counts are above 350
2. Consider withholding biologic when CD4+ <200
3. Joint care with multidisciplinary decision approach
anti‐TNF, anti‐tumour necrosis factor; HAART, highly active antiretroviral therapy; HBV, Hepatitis B virus; HCV, Hepatitis C virus; LFTs, liver function
tests; PCR, polymerase chain reaction.
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increase reactivity of peripheral T cells to antigen stimulation.82 Bio-
logics have an acceptable safety profile for use in patients with HCV
and is not contraindicated in concomitant HCV infection. However,
in the presence of acute HCV, anti‐TNF therapy is contraindicated.83
In the presence of chronic HCV, the decision to treat with anti‐TNF
depends on liver synthetic function. It is best avoided in patients
who are Child‐Pugh category B or C.83 HCV patients being treated
with anti‐TNF therapy should have close monitoring of aminotrans-
ferases with consideration for discontinuation of treatment with con-
tinued elevations.82 The guidelines from ECCO suggest cautious use
of antivirals due to drug interactions.65 Infection diagnosed whilst on
anti‐TNF therapy does not necessarily require cessation of therapy.65
There is no data yet on the use of newer antivirals for HCV in the
context of biologics use for IBD but there are no contraindications
for their concurrent use.
2.5.6 | Management
The ECCO guidelines are equivocal about screening for HCV prior to
use of immunosuppressive therapy.65 However, it would be prudent
to screen patients who are likely to need biologics considering the high
curative rates with newer anti‐viral drugs for HCV. All patients with
HCV infection should be discussed and managed jointly with hepatol-
ogy services, especially when biologics are indicated for IBD. During
the course of therapy, close monitoring of liver functions is key.
2.5.7 | HIV infection
The interaction between TNFα and the human immunodeficiency
virus (HIV) has been the subject of much scrutiny. The molecular
pathway by which HIV expression is upregulated by TNFα is well
described.84,85 Despite these findings, use of anti‐TNF in HIV‐patients
must be balanced with a potential increase in the risk of opportunistic
infections in patients with an attenuated immune system.
The evidence base for advice regarding use of biologics in
patients with HIV and IBD is limited. Within a cohort study and sev-
eral case reports, biologic therapy with infliximab in refractory IBD
patients has been demonstrated to be effective in inducing disease
remission with only a minority experiencing adverse effects.76–86 It is
important to note that initial CD4+ count in patients included in
these studies are >200 cells/mL. The ECCO guidelines65 also suggest
that the HIV‐IBD cohort of patients are less predisposed to infection
on highly active anti‐retroviral therapy (HAART) than if they did not
receive HAART. In this cohort, adverse effects have presented as
either a predisposition to infections, deranged CD4+ count or HIV
viral loads.
Abreu et al describe an HIV positive, thiopurine‐intolerant patient
treated with infliximab for a UC‐flare unresponsive to steroids87
who had been on ART (emtricitabine/tenofovir/efavirenz) with unde-
tectable HIV viral load & CD4+ count of 357/mmc prior to infliximab
therapy. Although excellent disease response was achieved, he was
diagnosed with listeriosis and was successfully treated. (CD4+ count
350/mmc). Infliximab was restarted with no clinical consequences. It
is likely that these patients with IBD remain at increased risk of
opportunistic infections.88
Other examples of adverse effects of biologics in HIV are
reported in the rheumatology cohort.89 In one case series,90 a
patient who was not on HAART therapy was observed to have an
increase in viral load (22 148‐428 503 c/ml) following initiation of
infliximab therapy. This required temporary cessation of infliximab
and the rise was not observed at readministration.
Within the limited evidence available, it is noted that patients do
benefit from adequate disease response with no specific HIV‐related
complications. Due to risk of AEs, it is recommended that screening
for HIV is undertaken prior to treatment with biologics and patients
with IBD recognised as HIV positive are managed by a multispecialty
team. Generally, in the absence of other infections treatment of HIV
infected patients with anti‐TNF is relatively safe. This group of
patients must ideally be on HAART. A discussion about potential
increased risk of infection, baseline blood tests including CD4+
count (ideally 200 cells/mL+), and HIV viral load is necessary. Close
monitoring throughout duration of therapy is key. An increase in
HIV viral load needs discussion with specialists and discontinuation
of biologic may become necessary. Any overt sign of infection merits
hospital admission to identify and treat the infection source and bio-
logics paused. Restarting biologics should be discussed based on clin-
ical aspects of each case. (Table 7)
2.6 | Fungal infections
Patients with IBD are known to be at an increased risk of fungal
infections. This is due to multiple factors such as severity of disease
activity, comorbidities, treatment with opioids, surgery, poor nutri-
tional status, leucopenia and older age.91 Another factor is immuno-
suppressive therapy, important of which are anti‐TNFs. A risk factor
analysis by one recent systematic review reported anti‐TNF therapy
as the predominant factor associated with fungal infections.91
2.6.1 | Aspergillosis
Aspergillosis, caused by Aspergillus fumigatus is a serious pulmonary
infection which warrants prompt diagnosis and treatment. Attenua-
tion of the inflammatory pathway through TNFα blockade alters the
cytotoxic immune response to fungal infections and in aspergillosis,
it is involved in polymorphonuclear leucocyte activation in response
to infection.92 The evidence is mostly from case reports. In 2001, a
case of invasive pulmonary aspergillosis was reported in a patient
with CD on anti‐TNF therapy.93 There have been other case reports
since but overall, it appears to be a rare occurrence. This usually pre-
sents initially with a poorly productive cough and can progress to
respiratory insufficiency; radiological changes are seen.93,94
2.6.2 | Management
The definitive diagnosis is on culture of broncho‐alveolar fluid. The
infection is treated with prolonged antifungal therapy based on
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sensitivities; amphotericin B or voriconazole or caspofungin is used.
The condition carries very poor prognosis. Concomitant tuberculous
cavity needs exclusion (Table 8).
2.6.3 | Histoplasmosis
This is another potential opportunistic infection reported in patients
exposed to anti‐TNF treatment. In a case series of ten immunocom-
promised subjects from an area endemic with histoplasmosis, 9 con-
tracted histoplasmosis shortly after commencing infliximab infusions.
Clinical presentation can be varied and include pulmonary, extrapul-
monary or disseminated disease symptoms which are nonspecific.95
2.6.4 | Management
Invasive fungal infections should be treated with systemic antifun-
gals and all immunosuppressant medication should be reviewed. The
FDA in 2008 have issued post market drug safety information alert-
ing healthcare providers that invasive fungal infections and histoplas-
mosis in patients receiving anti‐TNF drugs are not being swiftly
recognised, resulting in possible delays to patient therapy. The FDA
recommends the involvement of infectious diseases specialists96 in
the management of such cases (Table 8).
2.7 | Other Opportunistic infections
2.7.1 | Cytomegalovirus (CMV)
Cytomegalovirus (CMV) infection (detected by serology) could be
due to reactivation of latent infection during immunomodulator or
biologic therapy, but usually is itself mild or asymptomatic even on
immunosuppressants. However, CMV colitis, retinitis, pneumonia or
severe CMV infection during treatment of IBD requires further
assessment65 to plan management. Nevertheless, not all cases of
CMV infection in anti‐TNF use progress to CMV disease.97
The diagnosis of CMV disease using histopathology with
immunohistochemistry is highly sensitive and specific. This combined
with CMV viral load (CMV DNA detected by PCR in serum and tis-
sues) can provide most information about disease state.65 CMV viral
loads of >250 copies/mg is a predictor for patients presenting with
corticosteroid‐resistant disease.65
Cytomegalovirus disease manifesting as colitis is a recognised
complication of IBD and should be screened for in those patients
presenting with acute severe colitis.98 Typically, patients may have
had previous exposure to immunosuppressive therapy and experi-
enced prolonged corticosteroid therapy or corticosteroid‐refractory
disease. CMV can also be a cause of chronic pouchitis.99
2.7.2 | Management
It is important that diagnosis is established swiftly. When considered
as a differential diagnosis, testing for CMV viral load with PCR is
recommended to look for CMV disease especially in ill patients with
systemic manifestations. Histology and immunohistochemistry may
be used to support the diagnosis of CMV colitis. Once diagnosed,
ECCO recommend a 2‐3 week course of ganciclovir therapy for
CMV disease, and immunosuppressants are withheld.65 However, a
retrospective cohort case study of CMV‐positive colitides, identified
that patients with milder colitis were less likely to be treated, and
could respond to standard immunosuppressive therapy without addi-
tional treatment for CMV. CMV may be transiently reactivated and
disappear without antiviral therapy. In one study it was noted that
those with more severe disease were more likely to be treated with
ganciclovir, and were more likely to require either rescue therapy or
TABLE 8 Fungal infections with anti‐TNF therapy
Complication Diagnosis Management strategy
Candidiasis
Commonly localised infections but
systemic and invasive infection can
be life threatening
 Serology, culture and
molecular studies
1. Localised infections: Topical therapy
2. Invasive infections:
i Stop biologic
ii IV Fluconazole
iii Seek specialist advice
Aspergillosis
Pulmonary symptoms and invasive
infection
 Serology, culture and
imaging
1. Stop biologics
2. IV Anti‐fungal therapy (Consider IV voriconazole)
3. Caspofungin is another option
4. Specialist involvement
Histoplasmosis
Usually pulmonary infection
 Serology, culture and
radiology
1. Stop biologic therapy
2. Treatment with either one of:
i Amphotericin B initially and step‐down therapy to an azole
preparation
ii Itraconazole
Pneumocystis jirovecci  Clinical diagnosis Culture, microscopic and
molecular diagnosis
1. Cotrimoxazole 960 mg BD, if severe infection, increase to 1.44 g
BD
2. Specialist involvement
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surgery, despite adequate treatment of CMV.100 CMV colitis compli-
cating UC leading to acute severe colitis can be challenging to man-
age. A study by Kopylov et al reported the outcomes for patients
with severe colitis. Patients received infliximab/ciclosporin with gan-
ciclovir vs ganciclovir alone, and both groups had similar colectomy
rates.101 In patients who test positive for CMV whilst on anti‐TNF
therapy, there is evidence that anti‐TNF can be continued102
(Table 7).
2.7.3 | Pneumocystis pneumonia (PCP) or
Pneumocystis jirovecci pneumonia (PJP)
This is a serious infection reported in patients after use of
immunosuppressants. A large population based cohort study looked
at risk of PJP in IBD patients.103 Although there is some evidence
that the overall hazard risk of PJP in IBD is higher than normal
population, the absolute risk of PJP is considered to be very low
(0.03% in their cohort).103 In a large case series of PJP after inflix-
imab use, mean onset of symptoms reported was 21 days although
majority of patients were exposed to concomitant immunosuppres-
sive therapy. Over a quarter (27%) of patients died104 in these
reported series, so early recognition and therapy is paramount.
ECCO guidance recommends that patients on triple immunother-
apy with one being a calcineurin inhibitor or anti‐TNF should
receive standard prophylaxis with Trimethoprim‐sulfamethoxazole
(co‐trimoxazole) if tolerated. It should be considered in those on
dual immunosuppression especially if one is a calcineurin inhibi-
tor65 and in anti‐TNF regimens with associated corticosteroid
use.65 However, pill‐burden and side effects are to be kept in
mind. Cotrimoxazole is an effective option for prophylaxis and
active infection. Clinicians should discuss with their local microbiol-
ogy and infectious disease departments. Although more recent
studies report very low risk, clinicians have to be vigilant through-
out the course of treatment and decision on prophylaxis has to be
on a case‐by‐case basis (Table 8).
2.7.4 | Infection prevention and vaccination
recommendations
The main focus of the article is on management of adverse effects
and our stress on prevention, though very important, is limited as
these have been extensively addressed in ECCO guidelines. ECCO
guidance recommends that prior to immunosuppression, detailed his-
tory and examination, including prior bacterial, viral, and fungal infec-
tions, particularly herpes, VZV, TB exposure, prolonged travel/stay or
plans to travel to TB endemic or tropical areas and completion of
childhood vaccination programmes are documented. Further advice
should include cervical smear screening for women, food hygiene,
and avoidance of raw and unpasteurised foods. Education on safe
use and preparation of dairy & meat products can benefit patients at
risk of listeria infection whilst on anti‐TNF therapy. Live attenuated
vaccines must be avoided on immunomodulator or anti‐TNF therapy
and ideally patients should receive annual inactivated influenza vac-
cine and pneumococcal vaccine as required. Prior to the onset of
immunosuppression, consider vaccination with any outstanding rou-
tine vaccines plus HBV, VZV (if seronegative and no clinical history),
and HPV.65 If patients require live vaccines during therapy, the risk:
benefit assessment of vaccination should be undertaken. Patients
are usually immunocompetent within 3‐12 months105 after cessation
of therapy. Corticosteroid therapy alone is not considered to cause
significant immunocompromise unless high doses (20 mg or higher)
have been used continuously for more than 2 weeks.105
2.8 | Malignancy
Malignancies thought to be linked to immunosuppressive agents and
anti‐TNF use include solid organ malignancies, nonmelanoma skin
cancer (NMSC), melanoma, lymphoproliferative malignancies, and
those with viral association such as EBV‐related lymphomas and
HPV‐related cervical cancers, or dysplasia. However, difficulty
remains in establishing a cause‐effect relationship.
TABLE 9 Malignancies with anti‐TNF therapy
Complication Causative drug/s Diagnosis Management strategy
Melanoma Anti‐TNF  Clinical diagnosis Skin biopsy
1. Stop drug
2. Consider alternatives like Methotrexate or
vedolizumab
3. Dermatology involvement
Nonmelanoma skin cancer Dual anti‐TNF +thiopurine
therapy
 Clinical diagnosis Skin biopsy
1. Stop drug
2. Consider alternatives like Methotrexate or
vedolizumab
3. Dermatology involvement
Lymphoma
 HSTCL PTLD
Dual anti‐TNF +thiopurine
therapy
 Cross sectional
imaging Tissue biopsy
1. Stop drug
2. Consider switching drug class
Other malignancies:
Leukoencephalopathy
Dual anti‐TNF +thiopurine
therapy
 Clinical diagnosis Imaging Tissue biopsy
1. Stop the drug
2. Consider switching drug class
3. Relevant specialist involvement
anti‐TNF, anti‐tumour necrosis factor; HSTCL, hepatosplenic T‐cell lymphoma; PTLD, Post‐transplant lymphoproliferative disorder.
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A possible association between anti‐TNF use and malignancy first
arose from postmarketing reports to the FDA. There were 26 cases
of lymphoma reported in patients with rheumatoid arthritis or CD
disease treated with etanercept or infliximab.106 Further studies
demonstrated an increased risk for solid organ and NMSC in patients
treated with anti‐TNF and further immunosuppressive therapies.107
Many IBD patients are either on multidrug regimes or have had past
exposure to thiopurines (or other immunosuppressants) prior to anti‐
TNF usage.
Historically most trial data are from the rheumatology population.
A meta‐analysis derived from nine clinical trials of patients receiving
anti‐TNF treatment or placebo identified a number needed to harm
of 154 (95% CI: 91‐500) for 1 additional malignancy within a treat-
ment period of 6‐12 months.108 The malignancy rates were signifi-
cantly more common in those treated with higher doses (≥6 mg/kg
of infliximab every 8 weeks or 40 mg of adalimumab alternate
weeks).108 A more recent meta‐analysis of 74 randomised controlled
trials concerning adalimumab and infliximab showed no overall rela-
tive risk (RR) increase on short‐term follow‐up for malignancy with
the exception of NMSC which had a RR of 2.02 (95% CI: 1.11‐
3.95).109 A 6‐year follow‐up study from the national Danish registers
only identified three solid organ malignancies and one case of mela-
noma, with total follow‐up ranging from 0.1‐72.1 months.110 The
Crohn's therapy, resource, evaluation, and assessment tool (TREAT)
registry is collecting prospective data on large number of CD
patients to evaluate the long‐term safety of CD therapies. Data pub-
lished from the registry in 2006 showed mortality rates to be similar
between infliximab and non‐infliximab patient groups after a short
period of follow‐up (mean follow up 1.9 years).111 Subsequent data
from the registry published in 2014 (with follow‐up of up to
7.6 years) has shown that none of immunosuppressants, infliximab,
or combination therapy to be an independent risk factor for malig-
nancy.112 However, the follow‐up period remains short and future
analysis of the registry is likely to provide further evidence.
The CESAME Study Group113 assessed the impact of thiopurine
use on development of NMSC–comprised of basal cell carcinoma,
squamous cell carcinoma, and lymphoproliferative disorders (in-
creased risk found in the thiopurine group). Although a large number
of patients were included, the risk of malignancy secondary to bio-
logics could not be assessed due to relatively small number of
patients on these drugs.114 A study by Long et al published in 2010
assessed risk of malignancy and concluded that IBD in itself
increased risk of NMSC (incidence rate ratio IRR 1.64 95% CI: 1.51‐
1.78) and a nested case‐control model showed an increased risk
because of recent biologic use among patients with CD (adjusted
OR 2.07, 95% CI: 1.28‐3.33)115; patients on combination therapy
had the highest OR compared to medication‐free patients (OR 5.85
95% CI: 3.2‐10.8).115 Another study in 2012 reported that patients
were at higher risk of melanoma when exposed to biologics and
NMSCs were mainly related to thiopurine therapy.116 The most
recent French national cohort study showed an increased risk of
lymphoma in treatment exposed patients. When compared with
unexposed patients, the risk of lymphoma was higher among those
exposed to thiopurine monotherapy (aHR, 2.60; 95% CI: 1.96‐3.44;
P < 0.001), anti‐TNF monotherapy (aHR, 2.41; 95% CI: 1.60‐3.64;
P < 0.001), or combination therapy (aHR, 6.11; 95% CI: 3.46‐10.8;
P < 0.001).117
There remains concern about cases of hepatosplenic T‐cell lym-
phoma (HSTCL) (a rare and aggressive form of non‐Hodgkin's lym-
phoma affecting predominantly young men) occurring following
infliximab, adalimumab or thiopurine use. In a study published by
Thai et al, they reported 22 cases of HSTCL in IBD and most were
associated with thiopurine therapy either as monotherapy or in com-
bination with anti‐TNF. Whilst a link is recognised, quantifying this
risk to individual patients on current evidence is difficult.118 They
also concluded that despite the risk, benefits of treatment far out-
weighed the risks.118
Secondly, observational studies have noted a potential predispo-
sition to development of EBV related lymphoproliferative disorders
in IBD patients, in particular those treated with thiopurines and anti‐
TNF agents.65 Patients with EBV are predisposed to post‐transplant
lymphoproliferative disorders (PTLD), where T‐cell immune surveil-
lance is impaired.65 EBV related lymphomas may present in the gut,
rather than nodal sites. Screening for EBV should ideally be consid-
ered, however there is no current vaccination for EBV naïve
patients. In those developing EBV on therapy, treatment with antivi-
ral medication and withdrawal of therapy should be considered.65
IBD itself does not appear to increase risk of lymphoma diagnosis.119
However, use of a thiopurine for IBD or combination therapy with
an anti‐TNF may increase risk.119 Establishing any isolated effect of
anti‐TNF on lymphoma development is challenging. In a meta‐analy-
sis looking at lymphoma rates in CD patients treated with anti‐TNF,
two thirds of all patients were also receiving immunomodulator ther-
apies120; anti‐TNF treated patients appeared to have an increased
risk of lymphoma (SIR 3.23 95% CI: 1.5‐6.9) compared to the
expected population rate.120 The SIR was also increased when com-
pared to previously studied patients on immunomodulator therapy
alone (1.7 95% CI: 0.5‐7.1), however this did not reach statistical sig-
nificance.120 There were too few patients treated with isolated anti‐
TNF therapy to determine the individual risk of anti‐TNF usage on
lymphoma development.120
2.8.1 | Management principles in malignancy
The association between various malignancies and anti‐TNF treat-
ment remains unclear, but it is important that patients’ history of
previous or pre‐existing cancer is carefully documented prior to initi-
ation of biologic treatment. The use of biologics as monotherapy can
be considered in patients with previous history of cancer. Axelrad
et al noted that at 5 years after prior cancer diagnosis no significant
difference in cancer free survival could be demonstrated between
IBD treatment with anti‐TNF monotherapy, immunosuppressant
monotherapy, anti‐TNF combined with thiopurine therapy, though
numerically anti‐TNF monotherapy had the least cancer recur-
rence.121 In a meta‐analysis of 16 studies of immune mediated dis-
eases, including eight studies involving IBD patients, similar rates of
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cancer recurrence were observed among individuals affected by pre-
vious cancer who received no immunosuppressives, anti‐TNF
monotherapy, immunosuppressant therapy or combination thera-
pies.122 Therefore, in patients with a history of cancer, recent or
past, effective therapy for IBD can be used after consideration of
risks and benefits and discussion with oncologists. ECCO guidelines
also provide advice on managing IBD patients with previous history
of malignancy.123 Generally, among biologics, monotherapy anti‐TNF,
vedolizumab, or ustekinumab may all be used, but often thiopurines
are avoided (Table 9).
3 | CONCLUSION
The use of biologics is now a standard therapy for IBD used either
as monotherapy or in combination with immunomodulators. A
review of safety data of currently used biologics show cumulative
evidence for anti‐TNF as they have been used for longer duration. In
summary, acute infusion reactions are common with anti‐TNF, neu-
tropenia is a worrying AE and may require temporary cessation of
therapy. Infections are significantly higher with anti‐TNF which
include common and uncommon bacterial infections, mycobacterial
infections (in particular TB), viral and fungal infections, and oppor-
tunistic pathogens. Diagnostic and management strategies are out-
lined in separate tables.
Anti‐TNF therapy causes a wide range of dermatological presen-
tations. It is important to differentiate drug induced psoriasis from
psoriasiform rash. Treatment may range from topical therapy to anti‐
TNF withdrawal. Ustekinumab may be useful in these cases.
Malignancies thought to be linked to anti‐TNF use include solid
organ malignancies, NMSC, melanoma, lymphoproliferative malig-
nancies and those with a viral association. However, difficulty
remains in attributing a causal relationship particularly given the
confounding of thiopurine use. The link between HSTCL is recog-
nised but currently not quantified due to scarcity of data. IBD
increases risk for NMSC, with the risk further increased in combi-
nation therapy. The risk of lymphoma is increased with combination
therapy with thiopurines including EBV related lymphoma but it is
to be noted that results from the TREAT registry suggest that none
of the immunosuppressants, infliximab, or combination therapy are
an independent risk factor for malignancy. However, the follow‐up
duration remains short. Biologics can be used in patients with prior
history of cancer after careful discussion about risks and benefits
with oncologists.
Finally, although these therapies are often very effective, they
present unique challenges. It is likely that in the future biologics will
be used in a wider cohort of patients earlier in their disease journey,
and therefore prompt recognition of adverse events secondary to
drugs is important. Further reporting of rarer AEs and prompt
recording of common AEs in registries will help assess risk more
accurately. This information should help clinicians inform their
patients of risks associated with each therapy and will lead to more
informed decision making, thus improving patient care.
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